Jeffrey Eisele, Chief Development Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 10,414 shares at $65.58 ($683K) on 2024-01-17, disclosed to the SEC on 2024-01-18.
Scheduled sale ($683k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $65.58 | 5,207 | $341K | 50.0% |
| 2 | $65.58 | 5,207 | $341K | 50.0% |
| Total | $65.58 avg | 10,414 | $683K | 100% |
| Filing → |
| APLS | SELL | 2025-01-14 | $8K | — | Filing → |
| APLS | SELL | 2024-12-27 | $2K | — | Filing → |
| APLS | SELL | 2024-01-31 | $145K | — | Filing → |